Inclusion Criteria:  Males or females aged 18 years to 80 years at the time of screening. Ability to understand and willingness to sign a written informed consent document. Subjects must have advanced histologically or cytologically confirmed solid tumor or relapsed or refractory Non-Hodgkin lymphoma. Adequate bone marrow, liver, and renal functions. Men and women of childbearing potential must agree to take highly effective contraceptive methods. Women of reproductive potential must have negative serum beta human chorionic gonadotropin (β -HCG) pregnancy test within 7 days of the first dose.  Exclusion Criteria:  Receipt of systemic anticancer therapy including investigational agents or devices within 5 half-lives of the first dose of study treatment. Known active CNS metastasis. Has received a live-virus vaccine within 28 days. History of clinically significant sensitivity or allergy to monoclonal antibodies and their excipients or known allergies to antibodies produced from Chinese hamster ovary cells. Abnormality of QT interval or syndrome. Patients with history of Grade ≥ 3 immune-related AEs (irAEs) or irAE. Patients who receive concurrent or prior use of an immunosuppressive agent within 4 weeks of the first dose of study drug. Previous exposure to anti-CD137 (eg, utomilumab, urelumab) antibodies. . Active or chronic autoimmune disease that has required systemic treatment in the past 3 years or who are receiving systemic therapy for an autoimmune or inflammatory disease. Has a clinically significant cardiac condition, including unstable angina, acute myocardial infarction within 6 months. Has an active infection before the first dose of study treatment. History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease.. Female patients who are pregnant or breastfeeding. Any evidence of severe or uncontrolled systemic disease. Any condition that the investigator or primary physician believes may not be appropriate for participating the study.